Grabagun digital COO Matthew Vittitow sells $3,805 in shares

Progyny COO Melissa Cummings sold 1,879 shares of the company's common stock for a total of $52,612 on October 14, 2026. The shares were sold at $28.00 per share, as per a Rule 10b5-1 trading plan established by Cummings on December 19, 2025. At the time of the sale, Progyny's stock was trading at $26.86 with a market capitalization of $2.11 billion.

Additionally, Cummings withheld 1,559 shares for tax purposes upon the vesting of restricted stock units, valued at $42,701. Following these transactions, she directly owns 66,496 shares of Progyny common stock. Progyny is currently rated as having great financial health and is considered undervalued based on Fair Value analysis.

The company reported strong second-quarter 2026 earnings, surpassing Wall Street expectations with adjusted earnings of $0.55 per share on revenue of $350.51 million. Despite this, the stock saw a decline following management's comments about a potential summer slowdown. Progyny has also secured major partnerships, including being chosen as the fertility benefits partner for CalPERS effective July 2027.

This has led to a price target increase to $33.00 from $31.00 by Citizens, maintaining a Market Outperform rating.